{"name":"TRACON Pharmaceuticals","slug":"tracon","ticker":"TCON","exchange":"NASDAQ","domain":"traconpharma.com","description":"TRACON Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for cancer and other serious diseases. The company's pipeline includes several promising candidates, including TRC105 and TRC253. TRACON has a strong presence in the oncology and immuno-oncology markets, with a focus on addressing unmet medical needs. With a growing pipeline and a strong management team, TRACON is well-positioned for future growth.","hq":"San Diego, CA, USA","founded":0,"employees":"","ceo":"Charles P. Theuer","sector":"Oncology / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":12045000,"revenueGrowth":0,"grossMargin":0,"rdSpend":12277000,"netIncome":-3588000,"cash":10105000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"TRC105 patent cliff ($0.0B at risk)","drug":"TRC105","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"TRC253","genericName":"TRC253","slug":"trc253","indication":"Other","status":"phase_1"},{"name":"TRC105 chimeric anti-CD105 antibody","genericName":"TRC105 chimeric anti-CD105 antibody","slug":"trc105-chimeric-anti-cd105-antibody","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Votrient","genericName":"Votrient","slug":"votrient","indication":"Renal cell carcinoma","status":"marketed"}]}],"pipeline":[{"name":"TRC253","genericName":"TRC253","slug":"trc253","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Votrient","genericName":"Votrient","slug":"votrient","phase":"marketed","mechanism":"Bone morphogenetic protein receptor type-1B, Cyclin-dependent kinase 11A, Cyclin-dependent kinase 11B","indications":["Renal cell carcinoma","Sarcoma of soft tissue"],"catalyst":""},{"name":"TRC105 chimeric anti-CD105 antibody","genericName":"TRC105 chimeric anti-CD105 antibody","slug":"trc105-chimeric-anti-cd105-antibody","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"TRACON Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"TRACON Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"TRACON Pharmaceuticals Announces Collaboration with Merck KGaA to Develop TRC253","summary":"TRACON Pharmaceuticals announced a collaboration with Merck KGaA to develop TRC253, a novel cancer therapy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQQkxJUWxRN2EyN2dGMDBRN3ZCX3BRTUhyUkNJLTRzNEJnRjVOVzhZSDI5MjNFU0phRHJBUTVHdVRTMkZjR1R4VG1GZTB5bmZkdHBDQWgyQXJNdG1oZXR6TTBkdVZsVVMyOHpWUzJuSTgxVmw2V0dQQ2pDUmpVM2NlbVY2cGJGNGQ0VEplZHk2ZjlGdURoUlVDeHltZFhhRTVRLVVQNHpRVlU0d0VDV0w4V0Vqb2o2eFpDcGhlWG81aDVDVVFMU2ZtdENvR0Y4bnFzRGVj?oc=5","date":"2024-07-30","type":"pipeline","source":"GlobeNewswire","summary":"TRACON Pharmaceuticals Announces it Will Wind Down Operations - GlobeNewswire","headline":"TRACON Pharmaceuticals Announces it Will Wind Down Operations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNNVk4OUtYOXlVTjQxWGdlSjVzNF8tVXh1cjdFOEZaeXNnblAzV0kyVlBRRTB4Vl9neW43S1JrLVBqcXllM1lzZjVUbEFaWlJ2a3lwdTJwR0x1QlBXTGgzazY4QXlnZkRXaEJHbE1jMGRnczFRdVA1Qlc5VjVEVFJlY2h4R3hmTXFRaWhzMGNxYUh3VVpzc2paVjZSU0l1c1J0?oc=5","date":"2024-07-01","type":"trial","source":"Yahoo Finance","summary":"TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform - Yahoo Finance","headline":"TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPRy1RT1pQaFBoNEtTQUZHM09HVFlIUHVFUWpwYlY5VDFYOVBQX3J6dXJZd0NtOUpKZFdPVnlweGtrUjlBS0VkTGdLOHkyc0xla1FXaDJ0RjN2Sng2RjFGUVBGS2QtSFpnRVYya3lIOHBlWUxiTGZkcnp0bnRELThxX2dNTlZRYmhOQ0hieFBWbUc?oc=5","date":"2023-11-21","type":"pipeline","source":"InvestorPlace","summary":"Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today? - InvestorPlace","headline":"Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQN1JxRkVKUVJaVmFFSGE5SThBM0t4aWFaQzhWWkRaLXNNTzRPS1pXT0kxUnBUaXBKYTdKTHpKc1BwTFVKWXJkQjJnMUNSS19qN1lJSE5RTkJfYktQa1ZkZXBiUUh5M01fU1MxcHFlS3JJOVo0ZWlmaW9xTkJtMUs4MkVEd0FWYUwwOEtfZWJlaWhsZW1ScFJxNHJncXlfQUpfbHhtX05zR2kyQWktLV9HVm9FSGR5amJqYUtCYm4wVU9NSU42WkVIMXNoYmgyRlE2VFRrMnRxS1duTFdYNE1meDBLLVdoQTlSZGJjQjB6ZC1RUmpfbDFlcm11X0NMNlRsaVNmdzZLSE1wYjJM?oc=5","date":"2023-11-20","type":"deal","source":"GlobeNewswire","summary":"TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment - GlobeNewswire","headline":"TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQME1IbzhlanpsWmg0NFhpTXdyQjRRcWQzR1luVGRSbklfY3I0R2VsS0xjeFVfYkIwX0xXbFNxNldhZXNtSURDR0gzQmVTdDQ2Q3c0bTR6TWxIc3FPa0I0ejBjXzVGeExwVmF6bVl6ZHZZZmZxcVhsdGFMQWlkTnRWdzlBNWZMOFlCcDNqb05OcVhSUlF3VVhzcXBRS2xCN19nMXdrazdDTy1VSXlMWW9wTWIxNGVpNVI3UDk5Umtzcm0wc3dacS1CV25DZjBkNkR2eTNKd3REWFE5NDA?oc=5","date":"2020-12-29","type":"pipeline","source":"GlobeNewswire","summary":"TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering - GlobeNewswire","headline":"TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE9lbmZXaExWQXZibHJGNm1HNG1VUzVRSzhGQm15Y3Z6OXdWT0dObTMtLUdEdFFSMVg3R2pzM2hSNHRrSWRZQ0Iyeg?oc=5","date":"2020-12-02","type":"deal","source":"StockInvest.us","summary":"Tracon Pharmaceuticals Stock Price Forecast. Should You Buy TCON? - StockInvest.us","headline":"Tracon Pharmaceuticals Stock Price Forecast. Should You Buy TCON?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ZVlV5Q1NiM0puQm5UZ25ZSG1iTlRSMDhTQkx1bVBzcF9nUWdqQkRtUDRQcHNUTXprWlRXV25LTm1mYmlFRzd6MFV0dVA5RDVnVGoxUi01M2dtNkQ2dWRz?oc=5","date":"2020-01-06","type":"pipeline","source":"ChartMill","summary":"TCON Stock Price, Quote & Chart | TRACON PHARMACEUTICALS INC (NASDAQ:TCON) - ChartMill","headline":"TCON Stock Price, Quote & Chart | TRACON PHARMACEUTICALS INC (NASDAQ:TCON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOR3o4aDZzTGNUZFhyaXBIR2QxLTZodExhb0t3MlNpS0d6aUVjTzVuWm5pa0dkWjFnd01pNmRXd19zYjA3bUZvekx3amxjZHQ3QUJOM2xONFRpWHJ0OHMyWmR6b0tyRktTdjczbXJlSXp2dE13RFRqVFJidjdvZXB1X3p6UXdwd2h2bi1nbURaZVI1TlI3ZHgxMXRqdl9LQQ?oc=5","date":"2016-09-28","type":"deal","source":"Fierce Biotech","summary":"J&J invests in, licenses oncology candidates to microcap Tracon - Fierce Biotech","headline":"J&J invests in, licenses oncology candidates to microcap Tracon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE16dDNsRGQ5eHo5V2dZTkZ2ckFubWNiMGc2QXFNckM0dGdjcjFYTTU2dHZkWWRhOE5YUnlKZ3NNbTRGRk9rdlo5cXpubmdBV1M3WjNwZHo2cUphdw?oc=5","date":"2016-08-12","type":"pipeline","source":"MarketBeat","summary":"TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis - MarketBeat","headline":"TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"TRC105","drugSlug":"angiopep-2-conjugated-endothelial-growth-factor-receptor-antibody","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_1":2,"marketed":1},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":["Exelixis","Agenus","Clovis Oncology"],"therapeuticFocus":["Oncology","Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":12045000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":12045000,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":346000,"period":"2021-12-31"},{"value":346000,"period":"2021-12-31"},{"value":346000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12277000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-3588000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":10105000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}